Last Update: Aug 21, 2026 An Open-label, Multicenter Study to Evaluate Pharmacokinetics, Safety and Tolerability up to 6 Years of Intravenous Secukinumab Infusions in Pediatric Participants With Juvenile Psoriatic Arthritis ClinicalTrials.gov Identifier: [NCT06751238](https://clinicaltrials.gov/ct2/show/NCT06751238) Novartis Reference Number:CAIN457G22101 [See if you Pre-qualify](#trial-eligibility "See if you Pre-qualify") All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation. ## Study Description The purpose of this study is to determine the PK, safety and tolerability of multiple doses of intravenous (i.v.) secukinumab in pediatric participants with JPsA This is a multicenter, open-label study with an optional treatment extension period to evaluate pharmacokinetics, safety and tolerability (up to 6 years) of i.v. secukinumab in pediatric patients with JPsA. Condition Juvenile Psoriatic Arthritis Phase Phase1 Overall Status Recruiting Number of Participants20 Start Date Sep 24, 2025 Completion Date Mar 11, 2031 Gender All Age(s) 2 Years - 17 Years (Child) ## Interventions Biological ### Secukinumab Intravenous secukinumab ## Eligibility Criteria Key Inclusion Criteria: \* Participants parent's or legal representative(s) written informed consent and child's assent, if appropriate, must be obtained before any study related activity or assessment is performed. Of note, if the participant reaches age of consent (as per local law) during the study, they will also need to sign the corresponding study ICF (Informed Consent Form). \* Males and females ≥2 years old to \\<18 years old at the time of screening. \* Confirmed diagnosis of JPsA according to the modified International League of Associations for Rheumatology (ILAR) classification criteria that must have occurred at least 6 months prior to screening. \* Active JPsA disease defined as ≥3 active joints (swollen or if not swollen must be both tender and limited range of motion) at baseline (BSL). \* Inadequate response (≥1 month) or intolerance to ≥1 Non-Steroidal Anti-Inflammatory Drug (NSAID) at screening. \* Inadequate response (≥2 months) or intolerance to ≥ 1 Disease Modifying Anti-Rheumatic Drug (DMARD) at screening. \* Concomitant use of the following second-line agents such as disease-modifying and/or immunosuppressive drugs to treat the JPsA will be allowed: \* Stable dose of methotrexate (MTX) (maximum of 20 mg/ m2 BSA/ week) for at least 4 weeks prior to the BSL visit, with folic/folinic acid supplementation (according to standard medical practice of the center). \* Stable dose of an oral corticosteroid (CS) at a prednisone equivalent dose of \\<0.2 mg/kg/day or up to 10 mg/day maximum, whichever is less, for at least 7 days prior to BSL. \* Stable dose of no more than one NSAID for at least 1 week prior to BSL. Key Exclusion Criteria: \* Participants with body weight less than 10 kg at screening. \* Use of other investigational drugs within 4 weeks or 5 half-lives of BSL, or until the expected pharmacodynamic effect has returned to BSL, whichever is longer. \* History of hypersensitivity to study drug or its excipients or to drugs of similar chemical classes. \* Participants with active inflammatory bowel disease or active uveitis at screening or BSL. \* Fulfilling diagnostic criteria for any International League of Associations for Rheumatology (ILAR ) juvenile idiopathic arthritis (JIA) category other than JPsA at BSL. \* Participants treated with prohibited medication \* Participants taking any non-biologic DMARD at screening except for MTX. \* Any medical or psychiatric condition which, in the investigator's opinion, would preclude the participant from adhering to the protocol or completing the study per protocol. Other inclusion/exclusion criteria may apply United States #### Levine Childrens Hospital Recruiting Charlotte,North Carolina,28203,United States ###### Sheetal Vora ###### Haley D Furr Phone: [+1 800 821 1535]() Email: #### University of Utah Recruiting Salt Lake City,Utah,84113,United States ###### Tressie Rollins Phone: [+1 415 515 8212]() Email: ###### Peter Chiraseveenuprapund #### Col Uni Med Center New York Presby Recruiting New York,New York,10032,United States ###### Marcela Arizabaleta Phone: [+1 646 317 1669]() Email: ###### Lisa Imundo #### Loma Linda University Health Recruiting Loma Linda,California,92354,United States ###### Wendy De La Pena ###### Monica Pizana Phone: [+1 909 558 5830]() Email: #### Childrens Hosp Pittsburgh UPMC Recruiting Pittsburgh,Pennsylvania,15224,United States ###### Vibha Chauhan Phone: [+1 412 692 6327]() Email: ###### Margalit Rosenkranz #### Cincinnati Childrens Hospital Recruiting Cincinnati,Ohio,45229,United States ###### Megan Quinlan-Waters Phone: [+1 513 636 7261]() Email: ###### Hermine Brunner #### Texas Arthritis Center Recruiting El Paso,Texas,79902,United States ###### Melissa Lopez Email: ###### Sanjay Chabra #### University of Florida Recruiting Gainesville,Florida,32610 8068,United States ###### Joel Ravel Email: ###### Christian Oliveros #### Univ Hosp Cleveland Medical Center Recruiting Cleveland,Ohio,44106-5028,United States ###### Katrina Gogin Phone: [+1 216 844 7164]() Email: ###### Ezequiel Borgia #### Legacy Emanuel Research Hosp Portland Recruiting Portland,Oregon,97232,United States ###### Daniel Joseph Kingsbury ###### Brenna Bogle Phone: [+1 503 413 5447]() Email: #### Ann and Robert H Lurie Childs Hosp Recruiting Chicago,Illinois,60611,United States ###### Tyler Sorensen Phone: [+1 312 227 4811]() Email: ###### Pooja Patel ## Worldwide Contacts If the location of your choosing does not feature any contact detail, please reach out using the information below. #### Novartis Pharmaceuticals Phone: [ 1-888-669-6682](tel:1-888-669-6682) Email: